CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

Abstract excerpt

Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers. However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance. To overcome these limitations, we created a novel small molecule, CUDC-101, which simultaneously inhibits histone deacetylase and the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HER2/EGFR in Cancer Research
• Share to Histone Deacetylase Inhibitors Research
• Share to Protein Degradation and Inhibitors